Mican Technologies
A Kyoto University spinout company having production technologies to generate high performance artificial blood cells from stem cells. Their Mylc cell series are highly controlled immature dendritic cells suitable for evaluation of efficacy of drug discovery and safety assessment. Recently launched cMylc kit is exclusively designed for COVID-19 vaccines and drug development. The coronavirus optimised optimized myeloid lineage cells works as host cells with giving stable and robust performances for your research on COVID-19.
7-day free trial · no credit card
Verified contacts
6
available on Kipplo
LinkedIn employees
9
11 to 50 range
Open roles
—
no listings
Distinct roles
6
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 6 verified contacts at Mican Technologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
6 contacts with verified email or phone · masked until revealed.
- KF
Kazuhisa Fushihara
最高執行責任者 · General Business & Management
EmailPhone - TS
Takeshi Sakata
Director of Business Development, Sales Department · Other
EmailPhone
Showing 2 of 6 verified contacts
Top roles at Mican Technologies
6 distinct titles indexed · top 6 shown.
- 1business development associate
- 1customer success manager
- 1director of business development, sales department
- 1team leader (research & development cum outsourced services)
- 1最高執行責任者
- 1管理部
Sign up to unlock all 6 contacts at Mican Technologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 6 verified contacts at Mican Technologies
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.